0001426332 2020-01-01 2020-12-31 0001426332 2021-03-10 0001426332 2020-06-30 shares iso4217:USD Yes Yes true FY 0001426332 --12-31 No No 10-K/A true 2020-12-31 2020 false 001-38853 NGM BIOPHARMACEUTICALS, INC. DE 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 650 243-5555 Common Stock, par value $0.001 per share NGM NASDAQ Accelerated Filer false true false false false 457000000 76692401 Portions of the registrant’s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> are incorporated by reference in Part III, Items <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-14</div> of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> EXPLANATORY NOTE We are filing this Amendment No. 1 to Annual Report on Form 10-K/A (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021 (the “10-K”). This Amendment is being filed solely to refile the certifications of our principal executive officer and principal financial officer as exhibits to this Amendment as required pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934. No attempt has been made in this Amendment to otherwise modify or update the other disclosures presented in the 10-K. This Amendment does not reflect events occurring after the filing of the original 10-K (i.e., those events occurring after March 15, 2021) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed with the SEC. Accordingly, this Amendment should be read in conjunction with the 10-K and our other filings with the SEC.